CAJ | 학술논문

目的：评价含铂两药联合化疗对老年晚期非小细胞肺癌的疗效及安全性。方法回顾分析60例年龄≥70岁、经病理确诊的晚期非小细胞肺癌患者，根据病理类型，鳞癌一线采用顺铂联合吉西他滨，非鳞癌采用顺铂联合培美曲塞，顺铂25mg/m2，d1~3，吉西他滨1000mg/m2，d1，8，培美曲塞500mg/m2，d1，21d为1个周期。结果60例患者均可评价疗效及不良反应。CR 0例，PR 20例，SD 28例，PD 12例，客观有效率为33.3%，疾病控制率为80%，中位无疾病进展时间为7.3个月，主要不良反应为乏力、白细胞下降、贫血、血小板下降、恶心、呕吐及便秘，未出现与化疗相关的死亡。结论对于PS评分好的老年人，含铂两药联合化疗对晚期非小细胞肺癌疗效确切、可靠，安全性较好，不良反应可耐受。
목적：평개함박량약연합화료대노년만기비소세포폐암적료효급안전성。방법회고분석60례년령≥70세、경병리학진적만기비소세포폐암환자，근거병리류형，린암일선채용순박연합길서타빈，비린암채용순박연합배미곡새，순박25mg/m2，d1~3，길서타빈1000mg/m2，d1，8，배미곡새500mg/m2，d1，21d위1개주기。결과60례환자균가평개료효급불량반응。CR 0례，PR 20례，SD 28례，PD 12례，객관유효솔위33.3%，질병공제솔위80%，중위무질병진전시간위7.3개월，주요불량반응위핍력、백세포하강、빈혈、혈소판하강、악심、구토급편비，미출현여화료상관적사망。결론대우PS평분호적노년인，함박량약연합화료대만기비소세포폐암료효학절、가고，안전성교호，불량반응가내수。
Objective To evaluate the efficacy and safety of platinum-based doublet chemotherapy for aged patients with advanced non-small cell lung cancer. Methods 60 aged patients(age>70) with advanced non-small cell lung cancer were retrospectively analyzed. As for squamous lung cancer, the first-line treatment was gemcitabine plus cisplatin, and for nonsquamous lung cancer was pemetrexed plus cisplatin, ervery 3 weeks. Results The efficacy and side effects were evaluated for all 60 patients. There were 0 case of CR, 20 cases of PR, 28 cases of SD and 12 cases of PD. The effective rate was 33.3%, disease control rate was 80%, progression free survival was 7.3 months, and main side effects included anergy, leucopenia, anemia, thrombopenia and emesis, without deaths. Conclusion The efficacy and safety of platinum-based doublet chemotherapy for aged patients with advanced non-small cell lung cancer were good and reliable, without unacceptable side effects.